Search results for: Oncology
Filter search results
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…will be curtailed, particularly if a drug is nearing price negotiation time. This could limit new indication launches, an important (and efficient) source of new treatment opportunities, particularly in oncology…
OHE at HTAi 2017: Meet the Team
13 June 2017
…ten potential elements of value, four familiar ones and six new. These are highlighted in a recent OHE-AIM report. Presentation: Extrapolation From Progression Free Survival To Overall Survival In Oncology…
OHE at HTAi Rome
12 July 2017
…Overall Survival (OS) in Oncology. This presentation looked at the methods used to extrapolate PFS to OS in the field of oncology, as well as at the key limitations, weaknesses…
Around the World in HTAs: Canada – Autonomous yet Collaborative
9 April 2025
…of the first HTA bodies in the world. This evolved into the Canadian Agency for Drugs and Technology in Health (CADTH) in 2006. CADTH administered the pan-Canadian Oncology Drug Review…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
…Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe. OHE’s Adrian Towse participated in a two-day workshop convened…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
…grow, adopting OBIs in cancer care represents a strategic opportunity to build on existing benefits of SC drug delivery, and further advance efficiency, sustainability, and patient-centred service delivery across oncology….
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…medicine (a “follow-on” indication). This represents a hugely important and growing route to new treatment options for many patients, particularly in oncology, immunology, and rare diseases, among others. Adopting policies…
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
…be phased in progressively according to the following timelines. From 2025: new active substances (NAS) in oncology, advanced therapy medicinal products (ATMPs), and selected high-risk medical devices From 2028: orphan (rare disease) medicines…
Unlocking the Value of Combination Therapies
9 July 2024
…CTs are increasingly being used in oncology. Key takeaways The current approach to attributing value to therapies used in combination is the incremental value (IV) approach. However, this method faces…